Cornerstone Therapeutics (CRTX)
Cornerstone Therapeutics Revenues: 22.16M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CRTX Revenues Rankings
| Overall | 23rd percentile | 3398 of 4425 |
| Sector | 47th percentile | 247 of 470 in Healthcare |
| Industry | 66th percentile | 44 of 132 in Biotechnology |
CRTX Revenues Range, Past 5 Years
| Minimum | 3.219M | Sep 2007 |
| Maximum | 36.41M | Mar 2010 |
| Average | 22.40M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these CRTX related companies
CRTX News
From Earlier: Cornerstone Therapeutics Announces Court Orders Dismissal of CUROSURF(R) Case
May 25, 7:01AM Benzinga
May 25, 7:01AM Benzinga
Cornerstone Therapeutics to Acquire EKR Therapeutics, Accelerating Expansion in Hospital Market
May 14, 9:01PM Marketwire
May 14, 9:01PM Marketwire
Cornerstone Therapeutics Receives FDA Acceptance for CRTX 080 NDA for Treatment of Hyponatremia
Mar 13, 8:00AM Benzinga
Mar 13, 8:00AM Benzinga
Cornerstone Therapeutics (CRTX) Posts Surprise Q4 Loss of 6c/Share; Revs Light
Mar 08, 7:54AM Street Insider
Mar 08, 7:54AM Street Insider
Cornerstone (CRTX) Sells Product Rights of Factive Tablets, Spectracef Family to Merus Labs (MSLI), Vansen
Mar 07, 8:47AM Street Insider
Mar 07, 8:47AM Street Insider
Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2011 Conference Call
Mar 02, 4:15PM Marketwire
Mar 02, 4:15PM Marketwire
Cornerstone Therapeutics, Inc. (CRTX) Misses Q3 EPS by 1c, Sales Fall Below Expectations
Nov 03, 9:49AM Street Insider
Nov 03, 9:49AM Street Insider
$CRTX $8.76 Powell Andrew Kenneth William officer (EVP, General Counsel) S 2,000 @ $8.63 amnt $17,260 own'd 98,100 proc'd ($260) 7/15/2011
about 313 days ago by canarionyc
about 313 days ago by canarionyc
$CRTX looking ready to run higher. look at this chart http://bit.ly/jt8HDz
about 369 days ago by brettgrendahl
about 369 days ago by brettgrendahl
Official MFI screen is back online! A few new picks too. $CRTX, small pharmaceutical. Good growth, clean balance sheet.
about 468 days ago by MagicDiligence
about 468 days ago by MagicDiligence
$CRTX Collard Craig A director officer 10% owner (President and CEO) sold 385,000 @ $6.02 totl $2,317,700.00 2010-12-16
about 525 days ago by canarionyc
about 525 days ago by canarionyc
$CRTX Lutz Steven Michael officer (Executive Vice President) sold 65,000 @ $6.02 totl $391,300.00 2010-12-16
about 525 days ago by canarionyc
about 525 days ago by canarionyc
Drug Pipeline Pulse Check: Novartis, Cornerstone, Exelixis, Depomed http://bit.ly/i1ncMF $NVS $CRTX $EXEL $DEPO
about 553 days ago by alacrapulse
about 553 days ago by alacrapulse
RT @Street_Insider: Cornerstone Therapeutics $CRTX to Voluntarily Withdraw Balacet(R) 325 from US Market
about 553 days ago by tradeticket
about 553 days ago by tradeticket
$CRTX another biotech to look out for. Was up 7% today with expected FDA Decision on 5/15/10
about 755 days ago by tradeticket
about 755 days ago by tradeticket
@angrybear168 I am not aware of any FDA decision for $CRTX. Can you send me a link with some info? I didnt see any mention on their website
about 782 days ago by BioRunUp
about 782 days ago by BioRunUp
so many stocks with earnings related catalyst today. I'll be watching $crtx $divx $brli for potential entry. also keep an eye on solars.
about 816 days ago by ivanhoff
about 816 days ago by ivanhoff
David Moskowitz now @ MadisonWilliams starts coverage of 2 little cos:Vanda $VNDA (Buy/$19 target) & Cornerstone Thera $CRTX (Buy/$8 target)
about 846 days ago by MikeHuckman
about 846 days ago by MikeHuckman
Top PEG Value Plays for 2010 - $NEP $CRTX $GFRE - http://bit.ly/8LLXG4
about 887 days ago by sumfolio
about 887 days ago by sumfolio
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CRTX | 5.04 | +0.05 | +1.00% | 131.14M |
| CRT | 38.30 | -0.39 | -1.01% | 229.80M |
| CRS | 46.44 | -1.12 | -2.35% | 2.373B |
| CSCO | 16.33 | -0.06 | -0.37% | 87.95B |
| CSCD | 4.10 | +0.02 | +0.49% | 58.22M |
| CSC | 26.62 | +0.17 | +0.64% | 4.128B |
| CSBK | 10.07 | -0.19 | -1.85% | 263.23M |
| DFS | 32.73 | +0.11 | +0.34% | 17.35B |
| DFR | 6.92 | +0.33 | +5.01% | 140.13M |
| DFG | 45.53 | +0.00 | +0.00% | 2.513B |
